This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Laster Scrutinizes Strike Suits in Theragenics Litigation

Stocks in this article: ATVI CVX

NEW YORK (The Deal) -- J. Travis Laster is a bold judge, and the Delaware vice chancellor was at his most aggressive in a Feb. 21 order where he asked very probing questions of the shareholders and lawyers who brought a fiduciary duty lawsuit challenging the $68 million sale of Theragenics to Juniper Investment. Several lawyers not involved in the matter say they've never seen anything like Laster's order, which may be the latest salvo in the Delaware courts' effort to rein in the shareholder litigation that follows virtually every merger or acquisition of a Delaware public company.

As is common, Theragenics shareholders sued to challenge the deal soon after it was announced Aug. 5 on the grounds that in approving the transaction the company's directors had violated their fiduciary duties. The parties agreed to a settlement, which requires judicial approval because the matter is styled as an action on behalf of the entire class of Theragenics shareholders, who approved the deal. Over 96% of the shares cast - a total of 64% of the total float - were voted in favor of the deal, which closed Oct. 29. Theragenics was a surgical device company.

On Friday, Laster issued an order in which he scheduled a May 5 hearing to approve the settlement and the attorneys' fees that the shareholders' counsel at Rigrodsky & Long PA are seeking. Most of the order was boilerplate, but one portion was not. Laster required Rigrodsky to answer several questions that reflect a deep skepticism about the conduct of the Theragenics litigation and similar cases. His order could indicate he's considering a reduction in how much Rigrodsky is paid.

The judge did ask similar questions in an order consolidating the shareholder litigation arising from the Activision Blizzard's (ATVI) buying back a control stake from Vivendi last year. But the answers there were meant to help Laster appoint lead counsel for the shareholder plaintiffs and that case isn't much help in pointing to how Laster's plans to use the information in the Theragenics proceeding.

Critics of suits like Theragenics' - a group that occasionally includes the Delaware judges who hear such matters - believe that the shareholder plaintiffs are mere figureheads and that their counsel choose to bring the cases and determine when to settle them. Shareholders themselves almost never receive additional payment. Instead, the companies agree to disclose additional facts about the merger negotiations or the way bankers arrived at a valuation for the company and as part of the settlement pay shareholders' counsel a fee that's generally hundreds of thousands of dollars per case.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs